Any feedback?
Information on EC 3.4.21.91 - Flavivirin
for references in articles please use BRENDA:EC3.4.21.91Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.4.21.91 FlavivirinSpecify your search results
Word Map
- 3.4.21.91
- polyprotein
- viruses
- ns4a
-
replicons
-
west
- ribavirin
-
anti-hcv
-
direct-acting
-
virologic
-
cirrhosis
-
flaviviral
- boceprevir
- flaviviruses
- encephalitis
-
pegylated
- flaviviridae
- telaprevir
-
subgenomic
-
rna-dependent
-
unwind
-
mosquito-borne
- asunaprevir
-
resistance-associated
-
daclatasvir
- simeprevir
-
hcv-infected
- coronaviruses
-
anti-dengue
- ntpase
-
peptidomimetic
-
nonnucleoside
-
hcv-specific
-
macrodomains
- drug development
-
treatment-naive
-
peginterferon
-
replicase
-
quasispecies
-
interferon-free
-
trans-cleavage
- alphavirus
-
positive-stranded
- sofosbuvir
- analysis
- molecular biology
-
rna-stimulated
- medicine
-
hcv-1b
- synthesis
- gt1
The enzyme appears in viruses and cellular organisms
Reaction Schemes
Selective hydrolysis of -Xaa-Xaa-/-Yaa- bonds in which each of the Xaa can be either Arg or Lys and Yaa can be either Ser or Ala
Synonyms
ns3 protease, nonstructural protein 3, ns2b-ns3 protease, ns3 serine protease, ns2b-ns3pro, ns2b/ns3 protease, ns3 proteinase, ns3pro, ns2b/ns3, zikv protease, 
more
top
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
NS2B-3 proteinase
-
-
-
-
Yellow fever virus (flavivirus) protease
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
154215-26-6
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
benzoyl-norleucyl-lysyl-lysyl-argininyl-7-amido-4-methylcoumarin + H2O
benzoyl-norleucyl-lysyl-lysyl-arginine + 7-amino-4-methylcoumarin
-
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
4-(aminomethyl)-Nalpha-benzoyl-N-[(1R)-4-carbamimidamido-1-(dihydroxyboranyl)butyl]-L-phenylalaninamide
cn-716, ZIKV protease in complex with a peptidomimetic boronic acid inhibitor reveals a cyclic diester between the boronic acid and glycerol, enzyme binding structure, binds to the active site, crystal structure analysis, detailed overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Arteritis
Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design.
Asthma
Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor.
Bluetongue
Bluetongue Virus Nonstructural Protein 3 Orchestrates Virus Maturation and Drives Non-Lytic Egress via Two Polybasic Motifs.
Bluetongue
Nonstructural protein 3 of bluetongue virus assists virus release by recruiting ESCRT-I protein Tsg101.
Bronchitis
Changes in nonstructural protein 3 are associated with attenuation in avian coronavirus infectious bronchitis virus.
Carcinoma, Hepatocellular
Correlation between secondary structure of an amino-terminal portion of the nonstructural protein 3 (NS3) of hepatitis C virus and development of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics.
Classical Swine Fever
Characterization of classical swine fever virus (CSFV) nonstructural protein 3 (NS3) helicase activity and its modulation by CSFV RNA-dependent RNA polymerase.
Classical Swine Fever
Identification and characterization of the NTPase activity of classical swine fever virus (CSFV) nonstructural protein 3 (NS3) expressed in bacteria.
Coinfection
Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins.
COVID-19
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.
Dengue
3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.
Dengue
A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease.
Dengue
A novel anti-NS2BNS3pro antibody-based indirect ELISA test for the diagnosis of dengue virus infections.
Dengue
A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.
Dengue
A small compound targeting the interaction between nonstructural proteins 2B and 3 inhibits dengue virus replication.
Dengue
A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture.
Dengue
Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors.
Dengue
Allosteric pocket of the dengue virus (serotype 2) NS2B/NS3 protease: In silico ligand screening and molecular dynamics studies of inhibition.
Dengue
Amidoxime prodrugs convert to potent cell-active multimodal inhibitors of the dengue virus protease.
Dengue
An In-Silico Investigation of Phytochemicals as Antiviral Agents against Dengue Fever.
Dengue
Analysis of secondary structure predictions of Dengue virus type 2 NS2B/NS3 against crystal structure to evaluate the predictive power of the in silico methods.
Dengue
Analysis of the domain interactions between the protease and helicase of NS3 in dengue and hepatitis C virus.
Dengue
Anti-dengue infectivity evaluation of bioflavonoid from Azadirachta indica by dengue virus serine protease inhibition.
Dengue
Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay.
Dengue
Antiviral activity of astragaloside II, astragaloside III and astragaloside IV compounds against dengue virus: Computational docking and in vitro studies.
Dengue
Antiviral Cationic Peptides as a Strategy for Innovation in Global Health Therapeutics for Dengue Virus: High Yield Production of the Biologically Active Recombinant Plectasin Peptide.
Dengue
Backbone (1)H, (13)C and (15)N resonance assignments of dengue virus NS2B-NS3p in complex with aprotinin.
Dengue
Binding mode of the activity-modulating C-terminal segment of NS2B to NS3 in the dengue virus NS2B-NS3 protease.
Dengue
Binding of low molecular weight inhibitors promotes large conformational changes in the dengue virus NS2B-NS3 protease: fold analysis by pseudocontact shifts.
Dengue
Binding specificity of polypeptide substrates in NS2B/NS3pro serine protease of dengue virus type 2: A molecular dynamics Study.
Dengue
C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.
Dengue
Catalytically active Dengue virus NS3 protease forms aggregates that are separable by size exclusion chromatography.
Dengue
Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses.
Dengue
Co-refolding of a functional complex of Dengue NS3 protease and NS2B co-factor domain and backbone resonance assignment by solution NMR.
Dengue
Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites.
Dengue
Computational insight into dengue virus NS2B-NS3 protease inhibition: A combined ligand- and structure-based approach.
Dengue
Computer Aided Screening of Phytochemicals from Garcinia against the Dengue NS2B/NS3 Protease.
Dengue
Conformational change study of dengue virus NS2B-NS3 protease using 19F NMR spectroscopy.
Dengue
Conformational Dynamics of the Dengue Virus Protease Revealed by Fluorescence Correlation and Single-Molecule FRET Studies.
Dengue
Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
Dengue
Controlled peptide solvation in portion-mixing libraries of FRET peptides: improved specificity determination for Dengue 2 virus NS2B-NS3 protease and human cathepsin S.
Dengue
Correction to Peptide-?-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes.
Dengue
Critical Effect of Peptide Cyclization on the Potency of Peptide Inhibitors against Dengue Virus NS2B-NS3 Protease.
Dengue
Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design.
Dengue
Crystallization, characterization and measurement of MAD data on crystals of dengue virus NS3 serine protease complexed with mung-bean Bowman-Birk inhibitor.
Dengue
Curcumin Allosterically Inhibits the Dengue NS2B-NS3 Protease by Disrupting Its Active Conformation.
Dengue
Cystargamide B, a cyclic lipodepsipeptide with protease inhibitory activity from Streptomyces sp.
Dengue
Cysteine Disulfide Traps Reveal Distinct Conformational Ensembles in Dengue Virus NS2B-NS3 Protease.
Dengue
Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
Dengue
Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity.
Dengue
Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target.
Dengue
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis.
Dengue
Dengue virus NS3 serine protease. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects.
Dengue
Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature.
Dengue
Design and Docking Studies of Peptide Inhibitors as Potential Antiviral Drugs for Dengue Virus NS2B/NS3 Protease.
Dengue
Design of new competitive dengue ns2b/ns3 protease inhibitors-a computational approach.
Dengue
Design, structure-based focusing and in silico screening of combinatorial library of peptidomimetic inhibitors of Dengue virus NS2B-NS3 protease.
Dengue
Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases.
Dengue
Detection and quantification of dengue virus using a novel biosensor system based on dengue NS3 protease activity.
Dengue
Development and utility of an in vitro, fluorescence-based assay for the discovery of novel compounds against dengue 2 viral protease.
Dengue
Development of a NS2B/NS3 protease inhibition assay using AlphaScreen® beads for screening of anti-dengue activities.
Dengue
Development of antiviral inhibitor against dengue 2 targeting Ns3 protein: In vitro and in silico significant studies.
Dengue
Discovering key residues of dengue virus NS2b-NS3-protease: New binding sites for antiviral inhibitors design.
Dengue
Discovery and SAR studies of methionine-proline anilides as dengue virus NS2B-NS3 protease inhibitors.
Dengue
Discovery of antiviral molecules for dengue: In silico search and biological evaluation.
Dengue
Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease.
Dengue
Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity.
Dengue
Discovery of Novel Small Molecule Inhibitors of Dengue Viral NS2B-NS3 Protease Using Virtual Screening and Scaffold Hopping.
Dengue
Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
Dengue
Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication.
Dengue
Erratum for Herrera et al., "T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses".
Dengue
Ethyl 4-(4-methylphenyl)-4-pentenoate from Vetiveria zizanioides Inhibits Dengue NS2B-NS3 Protease and Prevents Viral Assembly: A Computational Molecular Dynamics and Docking Study.
Dengue
Exploiting Dengue Virus Protease as a Therapeutic Target; Current Status, Challenges and Future Avenues.
Dengue
Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design.
Dengue
Expression, purification, and characterization of the RNA 5'-triphosphatase activity of dengue virus type 2 nonstructural protein 3.
Dengue
Expression, purification, and initial structural characterization of nonstructural protein 2B, an integral membrane protein of Dengue 2, in detergent micelles.
Dengue
Flavonoid from Carica papaya inhibits NS2B-NS3 protease and prevents Dengue 2 viral assembly.
Dengue
Flavonoids as noncompetitive inhibitors of Dengue virus NS2B-NS3 protease: inhibition kinetics and docking studies.
Dengue
Fragment-based molecular design of new competitive dengue Den2 Ns2b/Ns3 inhibitors from the components of fingerroot (Boesenbergia rotunda).
Dengue
Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries.
Dengue
Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor.
Dengue
Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction.
Dengue
Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery Web portal.
Dengue
Identification of B cell epitopes of dengue virus 2 NS3 protein by monoclonal antibody.
Dengue
Identification of fused bicyclic derivatives of pyrrolidine and imidazolidinone as dengue virus-2 NS2B-NS3 protease inhibitors.
Dengue
Identification of new potent inhibitors of dengue virus NS3 protease from traditional Chinese medicine database.
Dengue
Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease.
Dengue
Identification of potential hit compounds for Dengue virus NS2B/NS3 protease inhibitors by combining virtual screening and binding free energy calculations.
Dengue
Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation.
Dengue
In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.
Dengue
In vitro determination of dengue virus type 2 NS2B-NS3 protease activity with fluorescent peptide substrates.
Dengue
In vitro evaluation of novel inhibitors against the NS2B-NS3 protease of dengue fever virus type 4.
Dengue
In-silico identification and evaluation of plant flavonoids as dengue NS2B/NS3 protease inhibitors using molecular docking and simulation approach.
Dengue
Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease.
Dengue
Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1.
Dengue
Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives.
Dengue
Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease.
Dengue
Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3.
Dengue
Internal cleavage of hepatitis C virus NS3 protein is dependent on the activity of NS34A protease.
Dengue
Internally quenched fluorescent peptide libraries with randomized sequences designed to detect endopeptidases.
Dengue
Ligand-bound structures of the dengue virus protease reveal the active conformation.
Dengue
Luteolin escape mutants of dengue virus map to prM and NS2B and reveal viral plasticity during maturation.
Dengue
Mechanism of NS2B-mediated activation of NS3pro in dengue virus: molecular dynamics simulations and bioassays.
Dengue
Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection.
Dengue
Mitochondrial Import of Dengue Virus NS3 Protease and Cleavage of GrpEL1, a Cochaperone of Mitochondrial Hsp70.
Dengue
Modulation of the nucleoside triphosphatase/RNA helicase and 5'-RNA triphosphatase activities of Dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase.
Dengue
Monitoring of dengue viruses in field-caught Aedes aegypti and Aedes albopictus mosquitoes by a type-specific polymerase chain reaction and cycle sequencing.
Dengue
Monomeric nature of dengue virus NS3 helicase and thermodynamic analysis of the interaction with single-stranded RNA.
Dengue
Mutagenesis of the dengue virus type 2 NS3 proteinase and the production of growth-restricted virus.
Dengue
New binding site conformations of the dengue virus NS3 protease accessed by molecular dynamics simulation.
Dengue
NMR analysis of a novel enzymatically-active unlinked Dengue NS2B-NS3 protease complex.
Dengue
NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease.
Dengue
NMR and MD Studies Reveal That the Isolated Dengue NS3 Protease Is an Intrinsically Disordered Chymotrypsin Fold Which Absolutely Requests NS2B for Correct Folding and Functional Dynamics.
Dengue
Novel Dengue Virus-Specific NS2B/NS3 Protease Inhibitor, BP2109, Discovered by a High-Throughput Screening Assay.
Dengue
NS3 protease from flavivirus as a target for designing antiviral inhibitors against dengue virus.
Dengue
Optimization of Assay Conditions for Dengue Virus Protease: Effect of Various Polyols and Nonionic Detergents.
Dengue
Peptide derivatives as inhibitors of NS2B-NS3 protease from Dengue, West Nile, and Zika flaviviruses.
Dengue
Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors.
Dengue
Peptide-?-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes.
Dengue
Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors.
Dengue
Probing contacts of inhibitor locked in transition states in the catalytic triad of DENV2 type serine protease and its mutants by 1H, 19F and 15?N NMR spectroscopy.
Dengue
Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides.
Dengue
Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5.
Dengue
Product release is rate-limiting for catalytic processing by the Dengue virus protease.
Dengue
Production and characterization of a monoclonal antibody specific for NS3 protease and the ATPase region of Dengue-2 virus.
Dengue
Profiling of flaviviral NS2B-NS3 protease specificity provides a structural basis for the development of selective chemical tools that differentiate Dengue from Zika and West Nile viruses.
Dengue
Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
Dengue
Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells.
Dengue
Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro.
Dengue
Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine.
Dengue
Retraction notice to "Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design" [J. Mol. Biol. (2000) 301, 759-767].
Dengue
Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease.
Dengue
Screening of antiviral activities in medicinal plants extracts against dengue virus using dengue NS2B-NS3 protease assay.
Dengue
Selection of suitable detergents for obtaining an active dengue protease in its natural form from E. coli.
Dengue
Sensitive NMR Approach for Determining the Binding Mode of Tightly Binding Ligand Molecules to Protein Targets.
Dengue
Simultaneous uncoupled expression and purification of the Dengue virus NS3 protease and NS2B co-factor domain.
Dengue
Small molecule inhibitor discovery for dengue virus protease using high-throughput screening.
Dengue
Steady-state cleavage kinetics for dengue virus type 2 ns2b-ns3(pro) serine protease with synthetic peptides.
Dengue
Steady-State NTPase Activity of Dengue Virus NS3: Number of Catalytic Sites, Nucleotide Specificity and Activation by ssRNA.
Dengue
Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
Dengue
Structural Platform for Autolytic Activity of an Intact NS2B-NS3 Protease Complex from Dengue Virus.
Dengue
Structure activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies showed plant flavonoids as potential inhibitors of dengue NS2B-NS3 protease.
Dengue
Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses.
Dengue
Structure-Based Virtual Screening: Identification of a Novel NS2B-NS3 Protease Inhibitor with Potent Antiviral Activity against Zika and Dengue Viruses.
Dengue
Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease.
Dengue
Structure-guided fragment-based in silico drug design of dengue protease inhibitors.
Dengue
Structure-guided mutagenesis of active site residues in the dengue virus two-component protease NS2B-NS3.
Dengue
Study the antiviral activity of some derivatives of tetracycline and non-steroid anti inflammatory drugs towards dengue virus.
Dengue
Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates.
Dengue
Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis.
Dengue
Synthesis and biological evaluation of ?-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture.
Dengue
Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease.
Dengue
Synthesis and evaluation of novel S-benzyl- and S-alkylphthalimide- oxadiazole -benzenesulfonamide hybrids as inhibitors of dengue virus protease.
Dengue
Synthesis and molecular modelling studies of novel sulphonamide derivatives as dengue virus 2 protease inhibitors.
Dengue
Synthesis, structure-activity relationship and antiviral activity of indole-containing inhibitors of Flavivirus NS2B-NS3 protease.
Dengue
Synthetic peptide optimization improves the inhibition of dengue NS2B-NS3 protease and dengue replication in vitro.
Dengue
T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses.
Dengue
The dengue virus NS2B-NS3 protease retains the closed conformation in the complex with BPTI.
Dengue
The RNA helicase, nucleotide 5'-triphosphatase, and RNA 5'-triphosphatase activities of Dengue virus protein NS3 are Mg2+-dependent and require a functional Walker B motif in the helicase catalytic core.
Dengue
Thermodynamic study of the effect of ions on the interaction between dengue virus NS3 helicase and single stranded RNA.
Dengue
Thiazolidinone-Peptide Hybrids as Dengue Virus Protease Inhibitors with Antiviral Activity in Cell Culture.
Dengue
Two-stage ML Classifier for Identifying Host Protein Targets of the Dengue Protease.
Dengue
Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors.
Dengue
Yellow fever virus NS2B/NS3 protease: Hydrolytic Properties and Substrate Specificity.
Dengue
[Expression of Dengue virus type 2 nonstructural protein 3 and isolation of host proteins interacting with it].
Encephalitis
A P2 and P3 substrate specificity comparison between the Murray Valley encephalitis and West Nile virus NS2B/NS3 protease using C-terminal agmatine dipeptides.
Encephalitis
Improvement of the purification of Saint Louis encephalitis virus NS2B-NS3 recombinant protease expressed in Escherichia coli.
Encephalitis
Substrate-based peptidomimetic inhibitors of the Murray Valley encephalitis virus NS2B/NS3 serine protease: A P1-P4 SAR study.
Encephalitis, Japanese
Antiviral potential of 4-hydroxypanduratin A, secondary metabolite of Fingerroot, Boesenbergia pandurata (Schult.), towards Japanese Encephalitis virus NS2B/NS3 protease.
Encephalitis, Japanese
Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.
Encephalitis, Japanese
Characterization of nonstructural protein 3 of a neurovirulent Japanese encephalitis virus strain isolated from a pig.
Encephalitis, Japanese
Functional determinants of NS2B for activation of Japanese encephalitis virus NS3 protease.
Encephalitis, Japanese
Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses.
Encephalitis, Japanese
Identification of Cleavage Sites Proteolytically Processed by NS2B-NS3 Protease in Polyprotein of Japanese Encephalitis Virus.
Encephalitis, Japanese
Japanese encephalitis virus NS2B-NS3 protease binding to phage-displayed human brain proteins with the domain of trypsin inhibitor and basic region leucine zipper.
Encephalitis, Japanese
Japanese encephalitis virus NS2B-NS3 protease induces caspase 3 activation and mitochondria-mediated apoptosis in human medulloblastoma cells.
Encephalitis, Japanese
Monoclonal Antibody That Inhibits Cleavage Activity of Japanese Encephalitis Virus NS3.
Encephalitis, Japanese
NS2B/NS3 mutations enhance the infectivity of genotype I Japanese encephalitis virus in amplifying hosts.
Encephalitis, Japanese
Processing of Japanese encephalitis virus non-structural proteins: NS2B-NS3 complex and heterologous proteases.
Encephalitis, Japanese
The NS3 protease and helicase domains of Japanese encephalitis virus trigger cell death via caspase?dependent and ?independent pathways.
Encephalitis, Japanese
[Method for Japanese encephalitis virus NS3 protease activity analysis and high-throughput screening assay for inhibitors].
Encephalitis, St. Louis
Improvement of the purification of Saint Louis encephalitis virus NS2B-NS3 recombinant protease expressed in Escherichia coli.
Encephalitis, Tick-Borne
Generation and genetic stability of tick-borne encephalitis virus mutants dependent on processing by the foot-and-mouth disease virus 3C protease.
Encephalitis, Tick-Borne
NS2B/NS3 protease: allosteric effect of mutations associated with the pathogenicity of tick-borne encephalitis virus.
Encephalitis, Tick-Borne
Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors.
Encephalomyelitis, Venezuelan Equine
Stable, high-level expression of reporter proteins from improved alphavirus expression vectors to track replication and dissemination during encephalitic and arthritogenic disease.
Flavivirus Infections
TRAF6 Plays a Proviral Role in Tick-Borne Flavivirus Infection through Interaction with the NS3 Protease.
Gastroenteritis
Porcine transmissible gastroenteritis virus inhibits NF-?B activity via nonstructural protein 3 to evade host immune system.
Gastroenteritis, Transmissible, of Swine
Porcine transmissible gastroenteritis virus inhibits NF-?B activity via nonstructural protein 3 to evade host immune system.
Hepatitis
Analysis of Coronavirus Temperature-Sensitive Mutants Reveals an Interplay between the Macrodomain and Papain-Like Protease Impacting Replication and Pathogenesis.
Hepatitis
Assessment of substrate specificity of hepatitis G virus NS3 protease by a genetic method.
Hepatitis
Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle.
Hepatitis
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Hepatitis
RNA-Stimulated ATPase and RNA helicase activities and RNA binding domain of hepatitis G virus nonstructural protein 3.
Hepatitis A
Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design.
Hepatitis C
1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease.
Hepatitis C
A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease.
Hepatitis C
A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.
Hepatitis C
A high throughput assay of the hepatitis C virus nonstructural protein 3 serine proteinase.
Hepatitis C
A highly sensitive and selective LC-MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies.
Hepatitis C
A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
Hepatitis C
A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity.
Hepatitis C
A quantum mechanics/molecular mechanics study of the reaction mechanism of the hepatitis C virus NS3 protease with the NS5A/5B substrate.
Hepatitis C
A straightforward microwave method for rapid synthesis of N-1, C-6 functionalized 3,5-dichloro-2(1H)-pyrazinones.
Hepatitis C
A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
Hepatitis C
A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations.
Hepatitis C
Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.
Hepatitis C
Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
Hepatitis C
Achiral Pyrazinone-Based Inhibitors of the Hepatitis C Virus NS3 Protease and Drug Resistant Variants with Elongated Substituents Directed Towards the S2 pocket.
Hepatitis C
Activity of compounds from Taxillus sutchuenensis as inhibitors of HCV NS3 serine protease.
Hepatitis C
Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Hepatitis C
Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease.
Hepatitis C
Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease.
Hepatitis C
An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A.
Hepatitis C
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Hepatitis C
An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.
Hepatitis C
An uniquely purified HCV NS3 protease and NS4A(21-34) peptide form a highly active serine protease complex in peptide hydrolysis.
Hepatitis C
Analysis of aptamer binding site for HCV-NS3 protease by alanine scanning mutagenesis.
Hepatitis C
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
Hepatitis C
Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran.
Hepatitis C
Analysis of the domain interactions between the protease and helicase of NS3 in dengue and hepatitis C virus.
Hepatitis C
Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors.
Hepatitis C
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Hepatitis C
Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease.
Hepatitis C
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
Hepatitis C
Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase.
Hepatitis C
Beta-amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors.
Hepatitis C
Binding kinetics, potency, and selectivity of the hepatitis C virus NS3 protease inhibitors GS-9256 and vedroprevir.
Hepatitis C
Binding of a noncovalent inhibitor exploiting the S' region stabilizes the hepatitis C virus NS3 protease conformation in the absence of cofactor.
Hepatitis C
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Hepatitis C
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
Hepatitis C
Characterisation of the role of zinc in the hepatitis C virus NS2/3 auto-cleavage and NS3 protease activities.
Hepatitis C
Characterization of ATPase activity of a hepatitis C virus NS3 helicase domain, and analysis involving mercuric reagents.
Hepatitis C
Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.
Hepatitis C
Characterization of monoclonal antibodies against hepatitis C virus nonstructural protein 3: different antigenic determinants from human B cells.
Hepatitis C
Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase.
Hepatitis C
Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.
Hepatitis C
Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.
Hepatitis C
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
Hepatitis C
Comparative molecular dynamics simulation of Hepatitis C Virus NS3/4A protease (Genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strains.
Hepatitis C
Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication.
Hepatitis C
Comparison of Different Quantum Mechanical/Molecular Mechanics Boundary Treatments in the Reaction of the Hepatitis C Virus NS3 Protease with the NS5A/5B Substrate.
Hepatitis C
Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor.
Hepatitis C
Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form.
Hepatitis C
Computational study on the drug resistance mechanism of HCV NS3 protease to BMS-605339.
Hepatitis C
Conformational changes in human hepatitis C virus NS3 protease upon binding of product-based inhibitors.
Hepatitis C
Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry.
Hepatitis C
Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.
Hepatitis C
Correlation between secondary structure of an amino-terminal portion of the nonstructural protein 3 (NS3) of hepatitis C virus and development of hepatocellular carcinoma.
Hepatitis C
Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors.
Hepatitis C
Crystal structure of a human VH: requirements for maintaining a monomeric fragment.
Hepatitis C
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.
Hepatitis C
Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
Hepatitis C
Detection of hepatitis C virus genome in human serum by multi-targeted polymerase chain reaction.
Hepatitis C
Detection of hepatitis C virus helicase activity using the scintillation proximity assay system.
Hepatitis C
Determination of the stoichiometry of noncovalent complexes using reverse-phase high-performance liquid chromatography coupled with electrospray ion trap mass spectrometry.
Hepatitis C
Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.
Hepatitis C
Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors.
Hepatitis C
Development of a high throughput scintillation proximity assay for hepatitis C virus NS3 protease that reduces the proportion of competitive inhibitors identified.
Hepatitis C
Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
Hepatitis C
Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope.
Hepatitis C
Dimethylthiazolidine carboxylic acid as a rigid p3 unit in inhibitors of serine proteases: application to two targets.
Hepatitis C
Direct-acting and host-targeting HCV inhibitors: current and future directions.
Hepatitis C
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Hepatitis C
Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
Hepatitis C
Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection.
Hepatitis C
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.
Hepatitis C
Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).
Hepatitis C
Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.
Hepatitis C
Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution.
Hepatitis C
Discovery of novel phosphonate derivatives as hepatitis C virus NS3 protease inhibitors.
Hepatitis C
Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
Hepatitis C
Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.
Hepatitis C
Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France.
Hepatitis C
DNA immunization efficiently targets conserved functional domains of protease and ATPase/helicase of nonstructural 3 protein (NS3) of human hepatitis C virus.
Hepatitis C
DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response.
Hepatitis C
DNA vaccination for the induction of immune responses against hepatitis C virus proteins.
Hepatitis C
Docking studies of Pakistani HCV NS3 helicase: a possible antiviral drug target.
Hepatitis C
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Hepatitis C
Dynamic Interconversions of HCV Helicase Binding Modes on the Nucleic Acid Substrate.
Hepatitis C
Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
Hepatitis C
Easy-to-execute carbonylations: microwave synthesis of acyl sulfonamides using Mo(CO)(6) as a solid carbon monoxide source.
Hepatitis C
Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication.
Hepatitis C
Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection.
Hepatitis C
Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity.
Hepatitis C
Effects of the Q80K Polymorphism on the Physicochemical Properties of Hepatitis C Virus Subtype 1a NS3 Protease.
Hepatitis C
Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3.
Hepatitis C
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Hepatitis C
Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein.
Hepatitis C
Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity.
Hepatitis C
Establishment of a cell-based assay system for hepatitis C virus serine protease and its primary applications.
Hepatitis C
Establishment of a simple assay in vitro for hepatitis C virus NS3 serine protease based on recombinant substrate and single-chain protease.
Hepatitis C
Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors.
Hepatitis C
Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection.
Hepatitis C
Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Hepatitis C
Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3.
Hepatitis C
Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design.
Hepatitis C
Exploring the P2 and P3 ligand binding features for Hepatitis C virus NS3 protease using some 3D QSAR techniques.
Hepatitis C
Expression and purification of a hepatitis C virus NS3/4A complex, and characterization of its helicase activity with the Scintillation Proximity Assay system.
Hepatitis C
Expression and purification of hepatitis C virus protease from clinical samples.
Hepatitis C
Expression of a hepatitis C virus NS3 protease-NS4A fusion protein in Escherichia coli.
Hepatitis C
Expression of highly active recombinant NS3 protease domain of hepatitis C virus in E. coli.
Hepatitis C
Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation.
Hepatitis C
Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
Hepatitis C
Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in patients naive to direct antivirals.
Hepatitis C
Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus.
Hepatitis C
Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs.
Hepatitis C
Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients.
Hepatitis C
Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method.
Hepatitis C
Global Origin and Transmission of Hepatitis C Virus Nonstructural Protein 3 Q80K Polymorphism.
Hepatitis C
H1-A, a compound isolated from Fusarium oxysporum inhibits hepatitis C virus (HCV) NS3 serine protease.
Hepatitis C
Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses.
Hepatitis C
Hepatitis C NS3 protease inhibition by peptidyl-alpha-ketoamide inhibitors: kinetic mechanism and structure.
Hepatitis C
Hepatitis C NS3 protease: restoration of NS4A cofactor activity by N-biotinylation of mutated NS4A using synthetic peptides.
Hepatitis C
Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
Hepatitis C
Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation.
Hepatitis C
Hepatitis C Virus Genotype 1-6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
Hepatitis C
Hepatitis C Virus Helicase Binding Activity Monitored through Site-Specific Labeling Using an Expanded Genetic Code.
Hepatitis C
Hepatitis C Virus NS3 Protease and Helicase Inhibitors from Red Sea Sponge (Amphimedon) ?Species in Green Synthesized Silver Nanoparticles Assisted by in Silico Modeling and Metabolic Profiling.
Hepatitis C
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Hepatitis C
Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
Hepatitis C
Hepatitis C Virus NS3 Protease Inhibitors: Large, Flexible Molecules of Peptide Origin Shows Satisfactory Permeability Across Caco-2 Cells.
Hepatitis C
Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.
Hepatitis C
Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR.
Hepatitis C
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.
Hepatitis C
Hepatitis C virus-encoded NS2-3 protease: cleavage-site mutagenesis and requirements for bimolecular cleavage.
Hepatitis C
Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 c-terminal deleted protein.
Hepatitis C
High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon.
Hepatitis C
Homology model of the dengue 2 virus NS3 protease: putative interactions with both substrate and NS2B cofactor.
Hepatitis C
Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors.
Hepatitis C
Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein.
Hepatitis C
Identification of protons position in acid-base enzyme catalyzed reactions: the hepatitis C viral NS3 protease.
Hepatitis C
Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease.
Hepatitis C
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
Hepatitis C
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.
Hepatitis C
Immunoreactivity assessment of hepatitis C virus NS3 protease and NS5A proteins expressed in TOPO cloning system.
Hepatitis C
Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Hepatitis C
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
Hepatitis C
In vitro activity of hepatitis C virus protease NS3 purified from recombinant Baculovirus-infected Sf9 cells.
Hepatitis C
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
Hepatitis C
In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Hepatitis C
In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus.
Hepatitis C
In vitro cleavage of hepatitis C virus polyprotein substrates by purified recombinant NS3 protease.
Hepatitis C
In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis.
Hepatitis C
In Vitro Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir.
Hepatitis C
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.
Hepatitis C
In vitro studies on the activation of the hepatitis C virus NS3 proteinase by the NS4A cofactor.
Hepatitis C
In vivo determination of substrate specificity of hepatitis C virus NS3 protease: genetic assay for site-specific proteolysis.
Hepatitis C
In-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 protease.
Hepatitis C
Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities.
Hepatitis C
Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior.
Hepatitis C
Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.
Hepatitis C
Inhibition of hepatitis C virus NS3 function by antisense oligodeoxynucleotides and protease inhibitor.
Hepatitis C
Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain.
Hepatitis C
Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target.
Hepatitis C
Inhibition of the hepatitis C virus NS3 protease activity by Fv fragment of antibody 8D4.
Hepatitis C
Inhibitors of the hepatitis C virus NS3 protease with basic amine functionality at the P3-amino acid N-terminus: discovery and optimization of a new series of P2-P4 macrocycles.
Hepatitis C
Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy.
Hepatitis C
Interplay between NS3 protease and human La protein regulates translation-replication switch of Hepatitis C virus.
Hepatitis C
Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma?
Hepatitis C
Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.
Hepatitis C
Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease.
Hepatitis C
Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum.
Hepatitis C
Isolation of scFvs that inhibit the NS3 protease of hepatitis C virus by a combination of phage display and a bacterial genetic screen.
Hepatitis C
Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus.
Hepatitis C
Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease.
Hepatitis C
Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease.
Hepatitis C
Longer wavelength fluorescence resonance energy transfer depsipeptide substrates for hepatitis C virus NS3 protease.
Hepatitis C
Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
Hepatitis C
Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
Hepatitis C
Melting of Duplex DNA in the Absence of ATP by the NS3 Helicase Domain through Specific Interaction with a Single-Strand/Double-Strand Junction.
Hepatitis C
Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization.
Hepatitis C
Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A.
Hepatitis C
Multiple determinants influence complex formation of the hepatitis C virus NS3 protease domain with its NS4A cofactor peptide.
Hepatitis C
Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy.
Hepatitis C
Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
Hepatitis C
Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients.
Hepatitis C
Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.
Hepatitis C
Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C.
Hepatitis C
Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors.
Hepatitis C
Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patient.
Hepatitis C
Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV.
Hepatitis C
Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.
Hepatitis C
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Hepatitis C
NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain.
Hepatitis C
NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.
Hepatitis C
Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.
Hepatitis C
Nonstructural protein 3 of hepatitis C virus blocks the distribution of the free catalytic subunit of cyclic AMP-dependent protein kinase.
Hepatitis C
Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions.
Hepatitis C
Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study.
Hepatitis C
Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Hepatitis C
Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
Hepatitis C
Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: Use of cyclopentane and cyclopentene P2-motifs.
Hepatitis C
Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease.
Hepatitis C
Novel, potent phenethylamide inhibitors of the hepatitis C virus (HCV) NS3 protease: probing the role of P2 aryloxyprolines with hybrid structures.
Hepatitis C
Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease.
Hepatitis C
NS3 protease from hepatitis C virus: biophysical studies on an intrinsically disordered protein domain.
Hepatitis C
NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
Hepatitis C
NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.
Hepatitis C
NS3 serine protease of bovine viral diarrhea virus: characterization of active site residues, NS4A cofactor domain, and protease-cofactor interactions.
Hepatitis C
Optimization of the multiple enzymatic activities of the hepatitis C virus NS3 protein.
Hepatitis C
Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-?, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice.
Hepatitis C
Organic anion transporting polypeptide-mediated transport of, and inhibition by, asunaprevir, an inhibitor of hepatitis C virus NS3 protease.
Hepatitis C
PBDE: Structure-Activity Studies for the Inhibition of Hepatitis C Virus NS3 Helicase.
Hepatitis C
PCR-Based In Vitro Synthesis of Hepatitis C Virus NS3 Protease for Rapid Phenotypic Resistance Testing of Protease Inhibitors.
Hepatitis C
Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position.
Hepatitis C
Peptides identified through phage display direct immunogenic antigen to dendritic cells.
Hepatitis C
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C.
Hepatitis C
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
Hepatitis C
Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
Hepatitis C
Physical methods to determine the binding mode of putative ligands for hepatitis C virus NS3 helicase.
Hepatitis C
Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Hepatitis C
Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.
Hepatitis C
Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue.
Hepatitis C
Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor.
Hepatitis C
Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics.
Hepatitis C
Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Hepatitis C
Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products.
Hepatitis C
Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease.
Hepatitis C
Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451.
Hepatitis C
Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
Hepatitis C
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).
Hepatitis C
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Hepatitis C
Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
Hepatitis C
Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides.
Hepatitis C
Protein backbone flexibility pattern is evolutionarily conserved in the Flaviviridae family: A case of NS3 protease in Flavivirus and Hepacivirus.
Hepatitis C
Protein kinase C recognizes the protein kinase A-binding motif of nonstructural protein 3 of hepatitis C virus.
Hepatitis C
Purification and characterization of the NS3 serine protease domain of hepatitis C virus expressed in Saccharomyces cerevisiae.
Hepatitis C
Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C.
Hepatitis C
Rapid and sharp decline in hepatitis C virus upon monotherapy with NS3 protease inhibitor, ACH-1625.
Hepatitis C
Recombinant baculovirus-expressed NS3 proteinase of hepatitis C virus shows activity in cell-based and in vitro assays.
Hepatitis C
Redesigning the substrate specificity of the hepatitis C virus NS3 protease.
Hepatitis C
Regulation of the biochemical function of motif VI of HCV NTPase/helicase by the conserved Phe-loop.
Hepatitis C
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
Hepatitis C
Rescuing compound bioactivity in a secondary cell-based screening by using ?-cyclodextrin as a molecular carrier.
Hepatitis C
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir.
Hepatitis C
Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Hepatitis C
Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
Hepatitis C
Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization.
Hepatitis C
Roles of the AX(4)GKS and arginine-rich motifs of hepatitis C virus RNA helicase in ATP- and viral RNA-binding activity.
Hepatitis C
SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells.
Hepatitis C
Screening and rank ordering of reversible mechanism-based inhibitors of Hepatitis C virus NS3 protease using electrospray ionization mass spectrometry.
Hepatitis C
SCREENING OF PROTEASE INHIBITORS RESISTANCE MUTATIONS IN HEPATITIS C VIRUS ISOLATES INFECTING ROMANIAN PATIENTS UNEXPOSED TO TRIPLE THERAPY.
Hepatitis C
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
Hepatitis C
Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
Hepatitis C
Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus.
Hepatitis C
Semliki Forest Virus replicon particles production in serum-free medium BHK-21 cell cultures and their use to express different proteins.
Hepatitis C
Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Hepatitis C
Significance of monoclonal antibodies against the conserved epitopes within non-structural protein 3 helicase of hepatitis C virus.
Hepatitis C
Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy.
Hepatitis C
Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Hepatitis C
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.
Hepatitis C
Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase.
Hepatitis C
Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease.
Hepatitis C
Solution and solid-phase synthesis of potent inhibitors of hepatitis C virus NS3 proteinase.
Hepatitis C
Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex.
Hepatitis C
Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain.
Hepatitis C
Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen design.
Hepatitis C
Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase.
Hepatitis C
Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus.
Hepatitis C
Structural characterization of the Hepatitis C Virus NS3 protease from genotype 3a: the basis of the genotype 1b vs. 3a inhibitor potency shift.
Hepatitis C
Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease.
Hepatitis C
Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors.
Hepatitis C
Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.
Hepatitis C
Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Hepatitis C
Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus.
Hepatitis C
Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.
Hepatitis C
Structure-thermodynamics-relationships of hepatitis C viral NS3 protease inhibitors.
Hepatitis C
Structure/function analysis of an RNA aptamer for hepatitis C virus NS3 protease.
Hepatitis C
Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.
Hepatitis C
Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase.
Hepatitis C
Supervised feature ranking using a genetic algorithm optimized artificial neural network.
Hepatitis C
Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
Hepatitis C
Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.
Hepatitis C
Synthesis of (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid vinyl-ACCA) derivatives: key intermediates for the preparation of inhibitors of the hepatitis C virus NS3 protease.
Hepatitis C
Synthesis of novel potent hepatitis C virus NS3 protease inhibitors: discovery of 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid as a N-acyl-L-hydroxyproline bioisostere.
Hepatitis C
T-cell antigenic determinants within hepatitis C virus nonstructural protein 3 and cytokine production profiles in hepatitis C.
Hepatitis C
Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual.
Hepatitis C
Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase).
Hepatitis C
The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor.
Hepatitis C
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.
Hepatitis C
The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.
Hepatitis C
The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Hepatitis C
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Hepatitis C
The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure.
Hepatitis C
The effect of the P1 side chain on the binding of optimized carboxylate and activated carbonyl inhibitors of the hepatitis C virus NS3 protease.
Hepatitis C
The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3).
Hepatitis C
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor.
Hepatitis C
The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
Hepatitis C
The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target.
Hepatitis C
The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.
Hepatitis C
The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
Hepatitis C
The macroscopic rate of nucleic acid translocation by hepatitis C virus helicase NS3h is dependent on both sugar and base moieties.
Hepatitis C
The metal binding site of the hepatitis C virus NS3 protease. A spectroscopic investigation.
Hepatitis C
The N-terminal region of hepatitis C virus nonstructural protein 3 (NS3) is essential for stable complex formation with NS4A.
Hepatitis C
The N-terminal region of NS3 serine proteinase of hepatitis C virus is important to maintain its enzymatic integrity.
Hepatitis C
The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase.
Hepatitis C
The NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activity.
Hepatitis C
The possible role of NS3 protease activity of hepatitis C virus on fibrogenesis and miR-122 expression in hepatic stellate cells.
Hepatitis C
The presence of additional resistance-related polymorphisms to NS3 protease inhibitors in hepatitis C virus sequences from the Los Alamos databank.
Hepatitis C
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Hepatitis C
The RNA-unwinding activity of hepatitis C virus non-structural protein 3 (NS3) is positively modulated by its protease domain.
Hepatitis C
Thermodynamics of zinc binding to hepatitis C virus NS3 protease: A folding by binding event.
Hepatitis C
Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature.
Hepatitis C
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.
Hepatitis C
Two Years' Persistence of Naturally Present Substitution R155K Within Hepatitis C Virus NS3 Protease in the Absence of Protease Inhibitor-based Therapy.
Hepatitis C
Unique Composite Active Site of the Hepatitis C Virus NS2-3 Protease: a New Opportunity for Antiviral Drug Design.
Hepatitis C
Use of a fluorescence plate reader for measuring kinetic parameters with inner filter effect correction.
Hepatitis C
Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors.
Hepatitis C
Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study.
Hepatitis C
Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3.
Hepatitis C
Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage.
Hepatitis C
[Cross-talk between ERK and NF-kappaB signal transduction pathways in the hepatocytes expressing hepatitis C virus nonstructural protein 3]
Hepatitis C
[Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 N-terminal protein]
Hepatitis C
[Mechanism of hepatocyte transformation by HCV NS3 using two-dimensional electrophoresis and mass spectrometry]
Hepatitis C
[Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
Hepatitis C, Chronic
Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease.
Hepatitis C, Chronic
All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection.
Hepatitis C, Chronic
Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.
Hepatitis C, Chronic
Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?
Hepatitis C, Chronic
Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials.
Hepatitis C, Chronic
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Hepatitis C, Chronic
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
Hepatitis C, Chronic
Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Hepatitis C, Chronic
Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
Hepatitis C, Chronic
Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Hepatitis C, Chronic
NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.
Hepatitis C, Chronic
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
Hepatitis C, Chronic
Pharmacokinetics of the NS3 Protease Inhibitor, Asunaprevir (ASV, BMS-650032), in Phase I Studies in Subjects With or Without Chronic Hepatitis C.
Hepatitis C, Chronic
Single and Multiple Ascending Dose Studies of the NS3 Protease Inhibitor, Asunaprevir, in Subjects With or Without Chronic Hepatitis C.
Hepatitis C, Chronic
Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Hepatitis C, Chronic
[Boceprevir: new possibilities for antiviral treatment of chronic hepatitis C].
Hepatitis C, Chronic
[Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Hepatitis, Chronic
Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics.
Infections
A fluorescence-activatable reporter of flavivirus NS2B-NS3 protease activity enables live imaging of infection in single cells and viral plaques.
Infections
A Hyperactive Kunjin Virus NS3 Helicase Mutant Demonstrates Increased Dissemination and Mortality in Mosquitoes.
Infections
Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease.
Infections
An Antiviral Peptide from Alopecosa nagpag Spider Targets NS2B-NS3 Protease of Flaviviruses.
Infections
An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.
Infections
Anti-dengue infectivity evaluation of bioflavonoid from Azadirachta indica by dengue virus serine protease inhibition.
Infections
Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.
Infections
Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
Infections
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
Infections
Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Infections
Conformational Dynamics of the Dengue Virus Protease Revealed by Fluorescence Correlation and Single-Molecule FRET Studies.
Infections
Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages.
Infections
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Infections
Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.
Infections
Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
Infections
Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant.
Infections
Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials.
Infections
Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection.
Infections
Discovery of Zika Virus NS2B/NS3 Inhibitors That Prevent Mice from Life-Threatening Infection and Brain Damage.
Infections
DNA vaccination for the induction of immune responses against hepatitis C virus proteins.
Infections
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Infections
Effect of bottlenecking on evolution of the nonstructural protein 3 gene of hepatitis C virus during sexually transmitted acute resolving infection.
Infections
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Infections
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Infections
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
Infections
Erratum for Herrera et al., "T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses".
Infections
Expression of the NS3 protease of cytopathogenic BVDV results in the induction of apoptosis but does not block activation of the interferon beta promoter.
Infections
Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.
Infections
Functional characterization of the NS2B/NS3 protease complex from seven viruses belonging to different groups inside the genus Flavivirus.
Infections
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Infections
Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation.
Infections
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Infections
Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation.
Infections
Identification of Cleavage Sites Proteolytically Processed by NS2B-NS3 Protease in Polyprotein of Japanese Encephalitis Virus.
Infections
Identification of new potent inhibitors of dengue virus NS3 protease from traditional Chinese medicine database.
Infections
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.
Infections
Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Infections
In silico evaluation of inhibitory potential of triterpenoids from Azadirachta indica against therapeutic target of dengue virus, NS2B-NS3 protease.
Infections
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
Infections
Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities.
Infections
Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy.
Infections
Investigating into the molecular interactions of flavonoids targeting NS2B-NS3 protease from ZIKA virus through in-silico approaches.
Infections
Isolation of scFvs that inhibit the NS3 protease of hepatitis C virus by a combination of phage display and a bacterial genetic screen.
Infections
Japanese encephalitis virus NS2B-NS3 protease induces caspase 3 activation and mitochondria-mediated apoptosis in human medulloblastoma cells.
Infections
Modulation of cellular immune response against hepatitis C virus nonstructural protein 3 by cationic liposome encapsulated DNA immunization.
Infections
Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
Infections
NMR and MD Studies Reveal That the Isolated Dengue NS3 Protease Is an Intrinsically Disordered Chymotrypsin Fold Which Absolutely Requests NS2B for Correct Folding and Functional Dynamics.
Infections
Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.
Infections
One Step Beyond: Design of Substrates Spanning Primed Positions of Zika Virus NS2B-NS3 Protease.
Infections
Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice.
Infections
Persistent Replication of a Chikungunya Virus Replicon in Human Cells Is Associated with Presence of Stable Cytoplasmic Granules Containing Nonstructural Protein 3.
Infections
Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
Infections
Recognition of the Murine Coronavirus Genomic RNA Packaging Signal Depends on the Second RNA-Binding Domain of the Nucleocapsid Protein.
Infections
Simple Indirect Enzyme-Linked Immunosorbent Assay to Detect Antibodies Against Bovine Viral Diarrhea Virus, Based on Prokaryotically Expressed Recombinant MBP-NS3 Protein.
Infections
Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Infections
T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses.
Infections
The effect of the P1 side chain on the binding of optimized carboxylate and activated carbonyl inhibitors of the hepatitis C virus NS3 protease.
Infections
Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining.
Infections
Viral Resistance in Hepatitis C Virus Genotype 1-Infected Patients Receiving the NS3 Protease Inhibitor Faldaprevir (BI 201335) in a Phase 1b Multiple-Rising-Dose Study.
Infections
Zika virus protease induces caspase-independent pyroptotic cell death by directly cleaving gasdermin D.
Lymphoma
HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution.
Medulloblastoma
Japanese encephalitis virus NS2B-NS3 protease induces caspase 3 activation and mitochondria-mediated apoptosis in human medulloblastoma cells.
Microcephaly
Inter-organelle interactions between the ER and mitotic spindle facilitates Zika protease cleavage of human Kinesin-5 and results in mitotic defects.
Neoplasms
Complex formation of the nonstructural protein 3 of hepatitis C virus with the p53 tumor suppressor.
Neoplasms
Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
Neoplasms
HCV NS3 protease enhances liver fibrosis via binding to and activating TGF-? type I receptor.
Neoplasms
Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 c-terminal deleted protein.
Neoplasms
Virtual ligand screening of the National Cancer Institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the West Nile Virus NS3 proteinase.
Neoplasms
[Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 N-terminal protein]
Persistent Infection
Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Persistent Infection
NS3 protease of genotype 3 subtype h HCV identified in southeastern France.
Persistent Infection
Visualizing hepatitis C virus infections in human liver by two-photon microscopy.
Rabies
Semliki Forest Virus replicon particles production in serum-free medium BHK-21 cell cultures and their use to express different proteins.
Severe Acute Respiratory Syndrome
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking.
Severe Acute Respiratory Syndrome
Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus.
Severe Acute Respiratory Syndrome
Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold.
Severe Acute Respiratory Syndrome
SARS coronavirus unique domain: three-domain molecular architecture in solution and RNA binding.
Severe Acute Respiratory Syndrome
Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3.
Severe Acute Respiratory Syndrome
The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase.
Severe Dengue
Cysteine Disulfide Traps Reveal Distinct Conformational Ensembles in Dengue Virus NS2B-NS3 Protease.
Vaccinia
Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication.
Vaccinia
Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites.
Virus Diseases
A novel anti-NS2BNS3pro antibody-based indirect ELISA test for the diagnosis of dengue virus infections.
Virus Diseases
Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans.
Virus Diseases
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Virus Diseases
Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection.
Virus Diseases
Doxycycline Interferes with Zika Virus Serine Protease and Inhibits Virus Replication in Human Skin Fibroblasts.
Virus Diseases
Fluorimetric and HPLC-based dengue virus protease assays using a FRET substrate.
Virus Diseases
Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in patients naive to direct antivirals.
Virus Diseases
Identification of fused bicyclic derivatives of pyrrolidine and imidazolidinone as dengue virus-2 NS2B-NS3 protease inhibitors.
Virus Diseases
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.
Virus Diseases
In vitro anti-HCV activities of Saxifraga melanocentra and its related polyphenolic compounds.
Virus Diseases
Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
Virus Diseases
Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.
Virus Diseases
Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine.
Virus Diseases
Sequestration of G3BP coupled with efficient translation inhibits stress granules in Semliki Forest virus infection.
Virus Diseases
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.
Virus Diseases
Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage.
West Nile Fever
Cell-active carbazole derivatives as inhibitors of the zika virus protease.
Yellow Fever
Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site.
Yellow Fever
Mutagenesis of the yellow fever virus NS2A/2B cleavage site: effects on proteolytic processing, viral replication, and evidence for alternative processing of the NS2A protein.
Yellow Fever
Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication.
Yellow Fever
Mutagenesis of the yellow fever virus NS2B/3 cleavage site: determinants of cleavage site specificity and effects on polyprotein processing and viral replication.
Yellow Fever
Mutation and docking studies on NS2b-NS3 complex from yellow fever virus towards drug discovery.
Yellow Fever
Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites.
Yellow Fever
Structural characterization and polymorphism analysis of the NS2B-NS3 protease from the 2017 Brazilian circulating strain of Yellow Fever virus.
Yellow Fever
Yellow fever virus NS2B-NS3 protease: characterization of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage activities.
Yellow Fever
Yellow fever virus NS2B-NS3 protease: charged-to-alanine mutagenesis and deletion analysis define regions important for protease complex formation and function.
Yellow Fever
Yellow fever virus NS2B/NS3 protease: Hydrolytic Properties and Substrate Specificity.
Zika Virus Infection
Analysis of cellular proteome changes in response to ZIKV NS2B-NS3 protease expression.
Zika Virus Infection
Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
physiological function
the Zika virus (ZIKV) relies on its NS2B/NS3 protease for polyprotein processing
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
purified ZIKV protease in complex with a peptidomimetic boronic acid inhibitor, X-ray diffraction structure determination and analysis at 2.7 A resolution
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Lei, J.; Hansen, G.; Nitsche, C.; Klein, C.D.; Zhang, L.; Hilgenfeld, R.
Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor
Science
353
503-505
2016
Zika virus (A0A140DLX4), Zika virus, Zika virus Brazilian isolate BeH823339 (A0A140DLX4)
brenda
EXTERNAL LINKS (specific for EC-Number 3.4.21.91)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
